Our role in the medical community is one we value very deeply. As a referral hospital we are a collaborative partner, establishing and maintaining clear lines of communications with referring physicians throughout treatment. We take leadership roles in
organizations that advance the way pediatric cancer and blood disorders are treated around the globe. And our fellowship program that has trained more leaders in the pediatric hematology and oncology field than any other. Continue reading to learn
more, or contact us to refer a patient or request a second opinion.
As a physician who wants the best for your patients, you can feel confident entrusting their care to Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
Our program brings together renowned hematologists and oncologists from Boston Children’s Hospital and Dana-Farber Cancer Institute. Our faculty is comprised of internationally recognized leaders, including David Williams, MD;
Lisa Diller, MD; Lindsay Frazier, MD; Holcombe Grier, MD;
Matthew Heeney, MD; Leslie Lehmann, MD;
Karen Marcus, MD; Stephen Sallan, MD; Suzanne Shusterman, MD; and Lewis Silverman, MD;
We surround our specialists with a vast community of pediatric subspecialists to provide your patient an unrivaled breadth of expertise across disciplines, including nursing, pathology, radiology, surgery, diagnostic imaging, neurology and orthopedics.
With over over 100 active clinical trials at any given time, we are at the forefront of innovation in the way pediatric cancer and blood disorders are diagnosed and treated. Among our many trials
are studies to develop innovative therapies such as immunotherapy and gene therapy.
We are also a leader in the integration of personalized medicine into treatment methodologies.
We offer several educational opportunities for physicians and medical students. Our continuing medical education (CME) courses cover a wide
range of current topics surrounding the treatment of pediatric oncology and hematology. Our experts are also frequent speakers at conferences and seminars, including the annual meetings for the American Society for Hematology (ASH), International
Society of Pediatric Oncology (SIOP) and the American Society of Pediatric Hematology/Oncology (ASPHO).
The Pediatric Hematology/Oncology Fellowship Program at Dana-Farber/Boston Children's is one of the most recognized in the nation. This program has trained more leaders
in the hematology and oncology field than any other. The objective of the training program is to provide the highest quality clinical and research training in hematology/oncology, so that our fellows become excellent clinicians and independent investigators
making substantive contributions to biomedical research.
A genetic test can explain why a child or young adult developed cancer and can help to predict whether he/she is at risk for other cancers.
Patients with hemophilia and other bleeding disorders are treated at the Boston Hemophilia Center, the largest hemophilia program in New England.
Our survivorship program provides care and advocacy for survivors of childhood cancer through ongoing education, support and research on the long-term effects of cancer treatments.
U.S. News & World Report ranked Dana-Farber/Boston Children's the #1 pediatric cancer hospital in the nation.
Not only are we a top cancer and blood disease center, we're also a top pediatric hospital. Above, our physicians explain how our vast clinical resources benefit patients.